Yuanqi Wang1, Huadong Chen2, Yixuan Liu3, Han Xiao4, Xiaoshuai Wang5, Zhihai Zhong2, Pengfei Gao2, Zhichong Zhang2, Jinbiao She2, Juncheng Liu2, Leilei Huang6, Hong Jiang7. 1. Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. 2. Department of Pediatric Surgery, The First Affiliated Hospital of Sun Yat-sen University, No. 58, ZhongShan 2nd Road, Guangzhou, 510080, China. 3. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China. 4. Division of Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, China. 5. Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, 510260, China. 6. Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, ZhongShan 2nd Road, Guangzhou, 510080, China. huangll43@mail.sysu.edu.cn. 7. Department of Pediatric Surgery, The First Affiliated Hospital of Sun Yat-sen University, No. 58, ZhongShan 2nd Road, Guangzhou, 510080, China. jiangh38@mail.sysu.edu.cn.
Abstract
PURPOSE: The present study aimed to explore the clinical characteristics and optimal treatments of RHB patients. METHODS: We retrospectively collected 42 RHB cases and 161 primary HB (PHB) cases. Clinical characteristics were compared between RHB and PHB patients. The risk factors related to overall survival (OS) and progression-free survival (PFS) in RHB patients were explored by COX regression analysis. Patients were further divided into curable and refractory subgroup by treatments. Propensity score match (PSM) analysis was performed to match recurrent curable patients from 145 curable PHB patients from the same cohort. PFS was further compared between 34 pairs of primary and recurrent curative HB patients. RESULTS: Recurrence treatment and number of relapsed tumors were significantly related with both OS and PFS of RHB patients (p < 0.05). Chemotherapy regimen alteration was also risk factor of PFS for RHB (HR = 4.26; 95% CI = 1.54-11.78; p = 0.005). RHB patients underwent curable treatment had better prognosis, compared with recurrent refractory subgroup (p < 0.001). Matched curable PHB patients demonstrated no significant difference of 3-year PFS with curable RHB patients (p = 0.540). CONCLUSION: Curable RHB patients might get benefit from surgery or ablation with similar prognosis with primary curable HB patients.
PURPOSE: The present study aimed to explore the clinical characteristics and optimal treatments of RHB patients. METHODS: We retrospectively collected 42 RHB cases and 161 primary HB (PHB) cases. Clinical characteristics were compared between RHB and PHB patients. The risk factors related to overall survival (OS) and progression-free survival (PFS) in RHB patients were explored by COX regression analysis. Patients were further divided into curable and refractory subgroup by treatments. Propensity score match (PSM) analysis was performed to match recurrent curable patients from 145 curable PHB patients from the same cohort. PFS was further compared between 34 pairs of primary and recurrent curative HB patients. RESULTS: Recurrence treatment and number of relapsed tumors were significantly related with both OS and PFS of RHB patients (p < 0.05). Chemotherapy regimen alteration was also risk factor of PFS for RHB (HR = 4.26; 95% CI = 1.54-11.78; p = 0.005). RHB patients underwent curable treatment had better prognosis, compared with recurrent refractory subgroup (p < 0.001). Matched curable PHB patients demonstrated no significant difference of 3-year PFS with curable RHB patients (p = 0.540). CONCLUSION: Curable RHB patients might get benefit from surgery or ablation with similar prognosis with primary curable HB patients.
Authors: Yan Shi; Sarah J Commander; Prakash M Masand; Andras Heczey; John A Goss; Sanjeev A Vasudevan Journal: J Pediatr Surg Date: 2017-03-16 Impact factor: 2.545
Authors: Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin Journal: Paediatr Drugs Date: 2012-08-01 Impact factor: 3.022
Authors: M Semeraro; S Branchereau; R Maibach; J Zsiros; M Casanova; P Brock; C Domerg; D C Aronson; A Zimmermann; V Laithier; M Childs; D Roebuck; G Perilongo; P Czauderna; L Brugieres Journal: Eur J Cancer Date: 2012-11-09 Impact factor: 9.162
Authors: Katarzyna B Hooks; Jérôme Audoux; Helena Fazli; Sarah Lesjean; Tony Ernault; Nathalie Dugot-Senant; Thierry Leste-Lasserre; Martin Hagedorn; Benoit Rousseau; Coralie Danet; Sophie Branchereau; Laurence Brugières; Sophie Taque; Catherine Guettier; Monique Fabre; Anne Rullier; Marie-Annick Buendia; Thérèse Commes; Christophe F Grosset; Anne-Aurélie Raymond Journal: Hepatology Date: 2018-05-14 Impact factor: 17.425